Anja Wuyts

Macrophage inflammatory protein-1

Macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta are highly related members of the CC chemokine subfamily. Despite their structural similarities, MIP-1alpha and MIP-1beta show diverging signaling capacities. Depending on the MIP-1 subtype and its NH(2)-terminal processing, one or more of the CC chemokine receptors CCR1, CCR2, CCR3 and CCR5 are recognized. Since both human MIP-1alpha subtypes (LD78alpha and LD78beta) and MIP-1beta signal through CCR5, the major co-receptor for M-tropic HIV-1 strains, these chemokines are capable of inhibiting HIV-1 infection in susceptible cells. In this review, different aspects of human and mouse MIP-1alpha and MIP-1beta are discussed, including their protein and gene structures, their regulated production, their receptor usage and biological activities and their role in several pathologies including HIV-1 infection.

AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice.

Autoimmune collagen-induced arthritis (CIA) in IFN-γR-deficient DBA/1 mice was shown to be reduced in severity by treatment with the bicyclam derivative AMD3100, a specific antagonist of the interaction between the chemokine stromal cell-derived factor-1 (SDF-1) and its receptor CXCR4. The beneficial effect of the CXCR4 antagonist was demonstrable when treatment was initiated between the time of immunization and appearance of the first symptoms. Treatment also reduced the delayed-type hypersensitivity response to the autoantigen, collagen type II. These observations are indicative of an action on a late event in the pathogenesis, such as chemokine-mediated attraction of leukocytes toward joint tissues. The notion of SDF-1 involvement was further supported by the observation that exogenous SDF-1 injected in periarthritic tissue elicited an inflammatory response that could be inhibited by AMD3100. The majority of leukocytes harvested from inflamed joints of mice with CIA were found to be Mac-1+ and CXCR4+, and AMD3100 was demonstrated to interfere specifically with chemotaxis and Ca2+ mobilization induced in vitro by SDF-1 on Mac-1+/CXCR4+ splenocytes. We conclude that SDF-1 plays a central role in the pathogenesis of murine CIA, by attracting Mac-1+/CXCR4+ cells to the inflamed joints.

HUMAN MONOCYTE CHEMOTACTIC PROTEINS-2 AND -3 : STRUCTURAL AND FUNCTIONAL COMPARISON WITH MCP-1

Structurally, the monocyte chemotactic proteins MCP‐1, ‐2, and ‐3 form a subfamily of the C‐C or β‐chemokines. Like other chemokines, MCPs are produced by a variety of cells on stimulation with cytokines (interleukin‐1, tumor necrosis factor‐α, interferon‐γ), bacterial and viral products or mitogens. MCP‐1 levels are enhanced during infection and inflammation, which are characterized by leukocyte infiltration. In vitro, MCPs are chemotactic for a distinct spectrum of target cells and show different specific biological activities depending on the cell type and the chemokine tested. MCP‐3 has the broadest range in that it activates monocytes, dendritic cells, lymphocytes, natural killer cells, eosinophils, basophils, and neutrophils. The most sensitive cells to all three MCPs are lymphocytes and monocytes. MCP‐1 is a potent basophil activator but does not attract eosinophils, whereas, at higher concentrations, MCP‐2 also stimulates both eosinophils and basophils. The signal transduction of MCPs on monocytes involves at least two G protein‐linked C‐C chemokine receptors: C‐C CKR‐1 binds MCP‐3 and C‐C CKR‐2 binds MCP‐1 and MCP‐3 but not MCP‐2. Receptor binding leads to enhanced [Ca2+]i for all chemokines except for MCP‐2.

Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1α

The chemokine stromal‐cell‐derived factor‐1α (SDF‐1α) chemoattracts lymphocytes and CD34+ haematopoietic progenitors and is the ligand for CXCR4 (CXC chemokine receptor 4), the main co‐receptor for T‐tropic HIV‐1 strains. SDF‐1α was NH2‐terminally cleaved to SDF‐1α(3‐68) by dipeptidyl‐peptidase IV (CD26/DPP IV), which is present in blood in soluble and membrane‐bound form. SDF‐1α(3‐68) lost both lymphocyte chemotactic and CXCR4‐signaling properties. However, SDF‐1α(3‐68) still desensitized the SDF‐1α(1‐68)‐induced Ca2+ response. In contrast to CD26/DPP IV‐processed RANTES(3‐68), SDF‐1α(3‐68) had diminished potency to inhibit HIV‐1 infection. Thus, CD26/DPP IV impairs the inflammatory and haematopoietic potency of chemokines but plays a dual role in AIDS.

The role of chemokines in inflammation

Chemokines, together with adhesion molecules, cytokines, and proteases, are essential for the directional migration of leukocytes during normal and inflammatory processes. Interleukin-8 and monocyte chemotactic protein-1 are the best-characterized members of the C-X-C and C-C chemokine subfamilies, respectively. However, more than 20 human chemokines have been identified but are only partially characterized at the biological level. Chemokines are involved in chemotaxis of monocytes, lymphocytes, neutrophils, eosinophils, basophils, natural killer cells, dendritic cells, and endothelial cells. This review describes the chemokine subfamilies, the chemokine producer and target cells, their receptors, singal transduction mechanisms, and the role of chemokines during physiological and pathological conditions. More and more evidence points to a role for chemokines in chemotaxis-related phenomena, such as the expression of adhesion molecules, the secretion of proteinases, inhibition of apoptosis, hematopoiesis, and angiogenesis. Chemokines are also involved in diseases such as cancer (tumor regression and tumor metastasis), autoimmune diseases, and bacterial or viral infection.

Granulocyte chemotactic protein-2 and related CXC chemokines: from gene regulation to receptor usage.

Chemokines contribute to the inflammatory response by selective attraction of various leukocytic cell types. Human GCP‐2 was originally identified by amino acid sequence analysis as a CXC chemokine co‐produced with IL‐8 by osteosarcoma cells. Furthermore, the complete coding domain of human GCP‐2 was disclosed by means of RT‐PCR. Similarly, mouse GCP‐2 was isolated from fibroblastoid and epithelial cells and completely identified by sequence analysis. Human and mouse GCP‐2 share 61% identical amino acids. Both chemokines occur as multiple NH2‐terminally truncated forms. The shorter forms of mouse, but not those of human, GCP‐2 showed a higher neutrophil chemotactic potency and gelatinase B releasing capacity. Mouse GCP‐2 was a more potent neutrophil activator than human GCP‐2, natural mouse KC, and MIP‐2. Human GCP‐2 was not chemotactic for monocytes, lymphocytes, or eosinophils. Quantitative studies of mRNA expression in diploid fibroblasts revealed GCP‐2 induction by IL‐1β. Human GCP‐2 induced [Ca2+]i increase in neutrophils, which was reciprocally desensitized by IL‐8, GROα, and ENA‐78. Human GCP‐2 induced [Ca2+]i increases and chemotactic responses in both CXCR1‐ and CXCR2‐transfected cells. Finally, GCP‐2 provoked neutrophil accumulation and plasma extravasation in rabbit skin. In humans, GCP‐2 complements the activity of IL‐8 as neutrophil chemoattractant and activator but it constitutes a major neutrophil chemokine in the mouse. GCP‐2 induces neutrophil chemotaxis and activation but it might also contribute to detrimental tissue damage in sepsis, acute respiratory distress syndrome, acute hypersensitivity reactions, and autoimmune diseases. It might also influence the invasive capacity of GCP‐2‐secreting tumor cells. J. Leukoc. Biol.62: 563–569; 1997.

The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine.

LD78alpha and LD78beta are 2 highly related nonallelic genes that code for different isoforms of the human CC chemokine macrophage inflammatory protein-1alpha (MIP-1alpha). Two molecular forms of natural LD78beta (7.778 and 7.793 kDa) were identified from conditioned media of stimulated peripheral blood mononuclear cells. Although LD78alpha and LD78beta only differ in 3 amino acids, both LD78beta variants were 100-fold more potent chemoattractants for mouse lymphocytes than was LD78alpha. On the contrary, LD78beta was only 2-fold more efficient than LD78alpha in chemoattracting human lymphocytes and monocytes. Using CC chemokine receptor-transfected cells, both molecular forms of LD78beta proved to be much more potent than LD78alpha in inducing an intracellular calcium rise through CCR5. Compared with LD78alpha and RANTES, this preferential binding of LD78beta to CCR5 resulted in a 10- to 50-fold higher potency in inhibiting infection of peripheral blood mononuclear cells by CCR5-using (R5) HIV-1 strains. To date, LD78beta is the most potent chemokine for inhibiting HIV-1 infection, and can be considered as a potentially important drug candidate for the treatment of infection with R5 HIV-1 strains.

Microbial Toll‐like receptor ligands differentially regulate CXCL10/IP‐10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN‐γ and provide a mechanism for enhanced synovial chemokine levels in septic arthritis

The CXC chemokine IFN‐γ‐inducible protein‐10 (IP‐10/CXCL10) activates CXC chemokine receptor 3 (CXCR3) and attracts activated T cells and natural killer cells. Peripheral blood mononuclearcells (PBMC) produce low but significant amounts of IP‐10/CXCL10 protein upon stimulation with double‐stranded (ds) RNA, the Toll‐like receptor 3 (TLR3) ligand. IFN‐γ is a superior IP‐10/CXCL10inducer. The bacterial TLR4 and TLR2 ligands, LPS and peptidoglycan (PGN), inhibit IFN‐γ‐ or dsRNA‐dependent IP‐10/CXCL10 production in PBMC, whereas IL‐8/CXCL8 production was enhanced. In fibroblasts a different picture emerges with IFN‐γ inducing moderate and dsRNA provoking strong IP‐10/CXCL10 production. Furthermore, treatment of fibroblasts with IFN‐γ in combination with bacterial LPS or PGN results in a synergistic production of IP‐10/CXCL10 and IL‐8/CXCL8. The synergistic induction of IP‐10/CXCL10 in fibroblasts is reflected by significantly enhanced IP‐10/CXCL10 concentrations in synovial fluids of septic compared to osteoarthritis patients to reach on average higher levels than those of IL‐8/CXCL8. These high amounts of IP‐10/CXCL10 produced by connective tissue fibroblasts not only attract CXCR3 expressing activated Th1 cells and natural killer cells to sites of infection but may also antagonize the CCR3 dependent attraction of Th2 lymphocytes and exert CXCR3‐independent, defensin‐like antibacterial activity.

CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity

The natural CC-chemokine RANTES(3-68), missing two NH2-terminal residues, has been isolated from leukocytes and tumor cells. The highly specific aminopeptidase dipeptidyl peptidase IV (DPP IV), also called CD26, was shown to be responsible for this NH2-terminal truncation of RANTES. Here it is reported that CD26/DPP IV treatment of RANTES enhances its anti-HIV-1 activity. RANTES(3-68) inhibited infection of PBMC by M-tropic HIV-1 strains ten-fold more efficiently than intact RANTES. This difference in antiviral potency between intact and truncated RANTES was even more pronounced (at least 25-fold) in CCR5-transfected cell lines. In HOS.CD4.CCR5 transfected cells, RANTES(1-68) had virtually no anti-HIV-1 activity (IC50 > 130 nM), whereas RANTES(3-68) was a potent inhibitor of HIV-1 replication (1C50: 5.5 nM). The anti-HIV-1 activity of RANTES(1-68) in the different cell types correlated with the expression of CD26. Moreover, the addition of soluble CD26 together with RANTES(1-68) significantly enhanced the antiviral activity of RANTES in HOS.CD4.CCR5 cells (IC50: 13 nM). These observations point to an important role of CD26-mediated processing of RANTES in inhibiting the replication of CCR5-binding HIV strains in HIV-infected persons and in preventing the development of AIDS.

Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl- peptidase IV

Chemokines are key players in inflammation and infection. Natural forms of the C-X-C chemokine granulocyte chemotactic protein-2 (GCP-2) and the C-C chemokine regulated on activation normal T cell expressed and secreted (RANTES), which miss two NH2-terminal residues, including a Pro in the penultimate position, have been isolated from leukocytes or tumor cells. In chemotaxis and intracellular calcium mobilization assays, the truncation caused a reduction in the specific activity of RANTES but not of GCP-2. The serine protease CD26/dipeptidyl-peptidase IV (CD26/DPP IV) could induce this observed NH2-terminal truncation of GCP-2 and RANTES but not that of the monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. No significant difference in neutrophil activation was detected between intact and CD26/DPP IV-truncated GCP-2. In contrast to intact natural RANTES(1–68), which still chemoattracts monocytes at 10 ng/ml, CD26/DPP IV-truncated RANTES(3–68) was inactive at 300 ng/ml and behaved as a natural chemotaxis inhibitor. Compared with intact RANTES, only a 10-fold higher concentration of RANTES(3–68) induced a significant Ca2+ response. Furthermore, RANTES(3–68) inhibited infection of mononuclear cells by an M-tropic HIV-1 strain 5-fold more efficiently than intact RANTES. Thus, proteolytic processing of RANTES by CD26/DPP IV may constitute an important regulatory mechanism during anti-inflammatory and antiviral responses.